Costs of revascularization over eight years in the randomized and eligible patients in the Emory Angioplasty versus Surgery Trial (EAST)

Am J Cardiol. 2000 Oct 1;86(7):747-52. doi: 10.1016/s0002-9149(00)01074-2.

Abstract

The Emory Angioplasty versus Surgery Trial (EAST) was a randomized trial that compared, by intention to treat, the clinical outcome and costs of percutaneous transluminal coronary angioplasty (PTCA) and coronary bypass grafting (CABG) for multivessel coronary artery disease. We present the findings of the economic analysis of EAST through 8 years of follow-up and compare the cost and outcomes of patients randomized in EAST versus patients eligible but not randomized (registry patients). Charges were assessed from hospital UB82 and UB92 bills and professional charges from the Emory Clinic. Hospital charges were reduced to cost through step-down accounting methods. All costs and charges were inflated to 1997 dollars. Costs were assessed for initial hospitalization and for cumulative costs of the initial hospitalization and additional revascularization procedures up to 8 years. Total 8-year costs were $46,548 for CABG and $44,491 for PTCA (p = 0.37). Cost of CABG in the eligible registry group showed a pattern similar to that for randomized patients, but total cost of PTCA was lower for registry patients than for randomized patients. Thus, the primary procedural costs of CABG are more than those for PTCA; this cost advantage, given the limits of measurement, is largely or even completely lost for randomized patients over the course of 8 years because of additional procedures after a first revascularization by PTCA.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Angioplasty, Balloon, Coronary / economics*
  • Coronary Artery Bypass / economics*
  • Coronary Disease / therapy*
  • Fees, Medical*
  • Female
  • Follow-Up Studies
  • Hospital Costs*
  • Humans
  • Male
  • Middle Aged
  • Statistics, Nonparametric
  • Treatment Outcome